Re: Kunimoto et al.: Efficacy and safety of abicipar in neovascular age-related macular degeneration: 52-week results of phase 3 randomized controlled study (Ophthalmology. 2020:127:1331–1334) 期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Re: Kunimoto et al.: Efficacy and safety of abicipar in neovascular age-related macular degeneration: 52-week results of phase 3 randomized controlled study (Ophthalmology. 2020:127:1331–1334)

摘要：
本文献已被 ScienceDirect 等数据库收录！